

Consumer Healthcare turnover

Three months ended 31 March 2014

			Total
	£m	CER%	AR%
Turnover			
Total wellness	416	(8)	(17)
Oral health	457	5	(5)
Nutrition	170	13	(3)
Skin health	84	(4)	(13)
Total	1,127	-	(10)

			Total
	£m	CER%	AR%
Turnover			
US	202	(10)	(15)
Europe	328	(4)	(7)
ROW	597	6	(9)
Total	1,127	-	(10)

Pharmaceuticals and Vaccines turnover – Three months ended 31 March 2014

	Total			USA			Europe			Emerging Markets			Japan		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
Respiratory	1,554	(11)	(17)	679	(20)	(25)	442	(3)	(4)	186	3	(9)	148	(3)	(20)
<i>Avamys/Veramyst</i>	70	(1)	(13)	8	(27)	(27)	18	12	6	17	25	6	23	(13)	(28)
<i>Flixotide/Flovent</i>	193	(2)	(9)	123	2	(5)	30	(9)	(9)	12	(7)	(20)	7	(10)	(30)
<i>Relvar/Breo</i>	3	-	-	1	-	-	2	-	-	-	-	-	1	-	-
<i>Seretide/Advair</i>	1,039	(15)	(21)	455	(30)	(34)	352	(3)	(5)	97	4	(8)	67	29	6
<i>Ventolin</i>	173	15	7	92	29	21	32	(3)	(3)	38	7	(7)	2	-	-
Other	76	(23)	(34)	-	-	-	8	-	-	22	(12)	(15)	48	(26)	(38)
Oncology	261	27	18	108	31	23	95	23	20	36	35	16	14	14	-
<i>Arzerra</i>	16	(24)	(24)	10	10	-	5	(55)	(55)	-	-	-	1	-	-
<i>Mekinist</i>	13	-	-	13	-	-	-	-	-	-	-	-	-	-	-
<i>Promacta</i>	48	30	20	18	19	13	16	45	45	5	40	-	8	50	33
<i>Tafinlar</i>	22	-	-	11	-	-	10	-	-	-	-	-	-	-	-
<i>Tyverb/Tykerb</i>	42	(13)	(19)	10	(27)	(33)	18	(10)	(14)	10	10	-	3	(25)	(25)
<i>Votrient</i>	87	31	23	37	18	12	37	42	42	9	57	29	2	50	-
Other	33	(3)	(11)	9	(36)	(36)	9	-	(10)	12	44	33	-	-	-
Cardiovascular, metabolic and urology (CVMU)	241	4	(5)	83	(19)	(23)	81	14	11	33	29	6	31	52	24
<i>Avodart</i>	199	7	(2)	59	(16)	(21)	71	9	8	26	29	8	31	52	24
Other	42	(8)	(16)	24	(24)	(27)	10	57	43	7	29	-	-	-	-
Immuno-inflammation	46	69	59	42	67	56	3	50	50	1	-	-	-	-	-
<i>Benlysta</i>	38	38	31	34	33	26	3	50	50	1	-	-	-	-	-
Other	8	-	-	8	-	-	-	-	-	-	-	-	-	-	-
Other pharmaceuticals	601	7	(3)	46	(28)	(31)	163	1	(1)	245	3	(11)	87	52	26
Dermatology	127	(14)	(22)	13	(58)	(61)	42	2	-	61	(4)	(16)	6	-	(14)
<i>Augmentin</i>	152	(6)	(13)	1	-	-	58	(5)	(6)	86	(7)	(17)	3	33	-
Other anti-bacterials	58	2	(5)	1	-	-	21	-	-	34	3	(11)	1	(100)	-
Rare diseases	106	4	(6)	24	(7)	(11)	33	6	6	8	-	(11)	37	5	(12)
Other	158	65	44	7	17	17	9	11	-	56	33	8	40	>100	>100
Innovative Pharmaceuticals	2,703	(2)	(10)	958	(15)	(20)	784	2	1	501	7	(7)	280	15	(4)
Vaccines	658	3	(3)	172	25	18	240	3	1	190	(8)	(16)	5	(45)	(55)
<i>Boostrix</i>	60	41	30	30	52	43	15	15	15	10	>100	>100	-	-	-
<i>Cervarix</i>	34	(5)	(15)	1	-	-	15	-	-	19	29	12	-	-	-
<i>Fluarix, FluLaval</i>	9	(27)	(40)	-	-	-	-	-	-	6	(22)	(33)	-	-	-
Hepatitis	120	(7)	(14)	44	(13)	(19)	46	2	-	19	(13)	(21)	-	-	-
<i>Infanrix, Pediarix</i>	202	20	13	71	100	87	92	(3)	(4)	23	(7)	(18)	-	-	-
<i>Rotarix</i>	86	16	8	26	-	(4)	18	64	64	34	19	10	5	20	-
<i>Synflorix</i>	62	(29)	(31)	-	-	-	12	8	-	49	(34)	(36)	-	-	-
Other	85	(4)	(8)	-	-	-	42	(2)	(7)	30	(6)	(14)	-	-	-
Innovative Pharmaceuticals and Vaccines	3,361	(1)	(9)	1,130	(10)	(16)	1,024	3	1	691	2	(10)	285	13	(6)
ViiV Healthcare (HIV)	311	4	(2)	122	3	(3)	125	(2)	(4)	30	22	4	13	28	6
<i>Combivir</i>	16	(48)	(52)	3	(67)	(69)	6	(57)	(58)	5	(7)	(17)	1	4	(14)
<i>Epzicom/Kivexa</i>	177	12	5	59	3	(3)	82	8	6	15	35	14	9	44	20
<i>Lexiva/Agenerase</i>	22	(11)	(19)	11	(26)	(30)	6	(19)	(21)	4	>100	100	1	(1)	(18)
<i>Selzentry</i>	33	(5)	(11)	12	(4)	(10)	15	2	-	1	(33)	(49)	1	(3)	(19)
<i>Tivicay</i>	31	-	-	26	-	-	4	-	-	-	-	-	-	-	-
<i>Trizivir</i>	11	(54)	(54)	3	(75)	(77)	6	(27)	(28)	-	-	-	-	-	-
Other	21	(21)	(25)	8	(33)	(33)	6	(25)	(25)	5	-	-	1	100	-
Established products	814	(11)	(19)	256	(17)	(22)	167	(12)	(14)	264	(7)	(17)	116	(2)	(19)
<i>Coreg</i>	32	6	(3)	32	6	-	-	-	-	-	-	-	-	-	-
<i>Hepsera</i>	23	(7)	(15)	-	-	-	-	-	-	17	(13)	(18)	6	16	(4)
<i>Imigran/Imitrex</i>	46	2	(4)	24	13	11	15	(9)	(11)	2	(17)	(25)	4	(18)	(32)
<i>Lamictal</i>	126	3	(5)	56	(9)	(15)	28	-	(2)	18	8	(5)	22	50	25
<i>Lovaza</i>	105	(25)	(29)	104	(25)	(29)	-	-	-	-	-	-	-	-	-
<i>Requip</i>	28	3	(10)	2	29	21	11	(27)	(28)	3	(9)	(21)	11	37	14
<i>Serevent</i>	27	(12)	(18)	9	(25)	(29)	13	(5)	(7)	1	(23)	(34)	3	4	(13)
<i>Seroxat/Paxil</i>	55	(15)	(25)	-	-	-	12	(14)	(15)	17	(17)	(26)	25	(6)	(22)
<i>Valtrex</i>	37	(24)	(33)	6	(40)	(44)	7	8	7	9	17	-	14	(36)	(47)
<i>Zeffix</i>	45	(16)	(21)	1	(63)	(65)	2	(20)	(21)	38	(14)	(19)	3	5	(13)
Other	290	(13)	(21)	22	(38)	(31)	79	(17)	(19)	159	(6)	(16)	28	(11)	(26)
	4,486	(3)	(10)												

The table above includes the sales by product reported in Other trading and unallocated pharmaceuticals segment (which includes Canada, Puerto Rico, Australasia, central vaccines tender sales and contract manufacturing sales) in the total column only. US dollar amounts shown above are a convenience translation of the sterling amounts.